Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma

I C MacLennan1, M Drayson, J Dunn

  • 1Department of Immunology, University of Birmingham Medical School.

BMJ (Clinical Research Ed.)
|April 16, 1994
PubMed
Summary
This summary is machine-generated.

This study explores multiple myeloma treatments, finding combination chemotherapy offers better response rates and symptom relief than conventional methods. While not curative, these therapies improve patient outcomes for this common bone cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The lymphocytes of splenic marginal zones: a distinct B-cell lineage.

Immunology today·2014
Same author

Observations of the effect of ionization-potential depression in hot dense plasma.

Physical review letters·2013
Same author

A systematic review of psycho-oncology research in Chinese populations: emerging trends.

European journal of cancer care·2013
Same author

2012 President's Plenary International Psycho-Oncology Society: future directions in psycho-oncology.

Psycho-oncology·2013
Same author

Multistate outbreak of Escherichia coli O145 infections associated with romaine lettuce consumption, 2010.

Journal of food protection·2013
Same author

Development and assessment of a biophysical dispersal model for sea lice.

Journal of fish diseases·2013
Same journal

Peptides: FDA appointed advisory committee criticised for conflicts of interest.

BMJ (Clinical research ed.)·2026
Same journal

Hantavirus outbreak linked to cruise ship is over, say officials.

BMJ (Clinical research ed.)·2026
Same journal

BMA recommends that 16 and 17 year olds get access to cross sex hormones.

BMJ (Clinical research ed.)·2026
Same journal

Andy Burnham could apply lessons from Manchester to create a healthier Britain with a stronger economy.

BMJ (Clinical research ed.)·2026
Same journal

Uganda confirms Marburg case as Ebola outbreak continues.

BMJ (Clinical research ed.)·2026
Same journal

Australia increases penalties for social media companies to enforce under 16s ban.

BMJ (Clinical research ed.)·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Multiple myeloma affects over 2000 individuals annually in England and Wales.
  • Common symptoms include bone pain, dehydration, and potential renal failure.
  • Current treatments are not curative but aim to manage the disease and its complications.

Purpose of the Study:

  • To evaluate the efficacy of different treatment strategies for multiple myeloma.
  • To identify patient groups who would benefit most from available therapies.
  • To assess the expected benefits and outcomes of current multiple myeloma treatments.

Main Methods:

  • Comparative analysis of combination chemotherapy versus conventional treatment.
  • Assessment of treatment response rates, including symptom relief and duration.

Related Experiment Videos

  • Evaluation of treatment-related hematological toxicity.

    • Main Results:

    • Combination chemotherapy (doxorubicin, carmustine, cyclophosphamide, melphalan) shows higher stable response rates than melphalan and prednisone.
    • Improved response rates were achieved without additional hematological toxicity.
    • Patients experienced significant bone pain reduction and prolonged symptom-free periods.

    Conclusions:

    • Combination chemotherapy represents an effective treatment for multiple myeloma, improving patient response and quality of life.
    • The study provides guidance on patient selection for optimal treatment benefits.
    • While relapse is common, initial combination therapy offers substantial palliation and symptom control.